This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

BASi Reports First Quarter Net Income Of $0.02 Per Share Versus A Prior Year First Quarter Net Loss Of $0.21 Per Share

Stocks in this article: BASI

Bioanalytical Systems, Inc. (NASDAQ:BASI) today announced financial results for the first quarter ended December 31, 2012.

Revenue decreased to $5,803,000, compared to $7,516,000 for the first quarter of fiscal 2012. Gross margin improved to 32.0% of revenue, compared to 19.7% a year ago. Operating income for this year’s first quarter increased to $302,000, versus an operating loss of $1,302,000 for the same period last year, driven by the increase in gross margin and a 44.2% reduction in operating expenses. Net income for the first quarter of fiscal 2013 was $139,000, or $0.02 per basic and diluted share. This compares to a net loss for the first quarter of fiscal 2012 of $1,491,000, or $0.21 per basic and diluted share.

EBITDA for this year’s first quarter was $851,000, versus an EBITDA loss of $704,000 for the first quarter of fiscal 2012. Cash provided by operations was $702,000 for the first quarter of the current fiscal year, versus $590,000 a year ago.

President & CEO and CFO Jacqueline Lemke said, "With the notable exception of revenue, all of our operating metrics moved decisively in the right direction in the first quarter compared to prior year. We believe these improvements are sustainable. Now we are implementing a strategy to restore revenue growth that builds on BASi’s competitive strengths - specialty assay and discovery capabilities, a long history of regulatory excellence, and our market-changing Culex NxT system. While it will take time for these initiatives to translate into higher sales for BASi, we expect to begin seeing positive results later this fiscal year.

"As we anticipated, our first quarter service revenue comparison was negatively affected by the consolidation of our Oregon laboratory into our West Lafayette facility and the closure of our UK lab in last year’s second half. Service revenue in the current quarter was also impacted by unexpected delays in the start of certain pharmaceutical analysis contracts. Although product sales have historically been strongest in the first quarter of the fiscal year, it appears that customers delayed orders in anticipation of the launch of our new advanced Culex® NxT in vivo sampling system. Supporting this view, product orders have picked up in the past few weeks, which is an encouraging sign for the future.

"On the service side, we recently announced the first of a number of collaborative research projects and preferred provider partnerships that we expect to contribute to revenue beginning this fiscal year. Additionally, we currently are interviewing to hire both a West Coast and an East Coast bioanalytical services sales representative to improve our reach across the United States, and have realigned sales compensation to incentivize new sales and reward winning business based upon referrals and reputation. We remain optimistic about the outlook for fiscal 2013.”

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,232.34 +163.47 0.96%
S&P 500 2,001.75 +29.01 1.47%
NASDAQ 4,619.0820 +71.2480 1.57%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs